Parkinson's disease
Conditions
Sponsors
First Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 to 75 years old, gender not limited; 2. Diagnosed with primary Parkinson's disease; 3. The efficacy of the drug has significantly declined, or obvious motor complications have occurred, affecting the patient's quality of life. Or intolerable adverse drug reactions occur, affecting the efficacy of the drug; 4. There is stiffness or tremor that cannot be fully controlled by medication; 5. The Hoehn-Yahr stage was at least 2.5 stages; 6. Voluntarily participate in clinical trials and be able to sign informed consent forms;
Exclusion criteria
Exclusion criteria: 1. I have received surgical damage treatment before; 2. Pregnant women, lactating women, women of childbearing age who plan to conceive or have no safe contraceptive measures; 3. Drug users and alcoholics; 4. Obvious cognitive impairment (MMSE <= 17 points for primary school students and <= 24 points for middle school students and above); 5. There is severe depression or other serious mental illness that cannot be treated; 6. Those with a history of craniocerebral injury, tumors, or severe cerebrovascular diseases; 7. Severe brain atrophy (confirmed by CT or MRI); 8. The implanted site needs to undergo hyperthermia therapy; 9. Abnormal blood routine and blood biochemical tests, coagulation dysfunction, and severe abnormalities in liver and kidney functions; 10. Uncontrollable hypertension, severe heart disease or serious internal or respiratory diseases; 11. Long-term use of immunosuppressants or hormone therapy is required; 12. There are other concomitant diseases, and a pacemaker, defibrillator, cochlear implant or other nerve stimulator needs to be implanted or has been implanted; 13. Due to other types of diseases, repeated MRI examinations are required; 14. Those who have participated in any other clinical trials within three months before the operation; 15. Unwilling or unable to cooperate with the human implantation surgery of deep brain stimulation system components; 16. Unwilling or unable to cooperate with postoperative follow-up; 17. Those that researchers consider unsuitable;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dopamine, TNF-a, IL-6, a -synuclein;Inflammation level;Inflammation level; | — |
Countries
China
Contacts
Public ContactGeng Xin
First Affiliated Hospital of Kunming Medical University
Outcome results
None listed